Study to Evaluate the Safety and Efficacy of Jaktinib in Adults With Alopecia Areata
A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Jaktinib in Adult Patients With Severe Alopecia Areata
In the register
The register attaches this trial to Jaktinib (Suzhou Zelgen Biopharmaceuticals), currently at “Approved” in the register. The programme's phase is checked by hand; the trial's is declared by its sponsor.
What the registry records
- Status
- Completed
- Declared phase
- Phase 3
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Participants (registry)
- 425
- Start
- September 2021
- Primary completion
- December 2023
- Study completion
- December 2023
- Last registry update
- March 2025
- Countries
- China
Conditions studied: Alopecia Areata
Interventions: Jaktinib, placebo
Other trials of Jaktinib
Extension Study to Evaluate Safety and Efficacy of Jaktinib in Adults With Alopecia Areata
A Study With Jaktinib Hydrochloride Cream Applied Topically to Subjects With Alopecia Areata
Study to Evaluate the Safety and Efficacy ofJaktinib Hydrochloride Tablets in Severe Alopecia Areata
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.